THURSDAY, Nov. 14, 2024 (HealthDay News) -- The U.S. Food and Drug Administration has approved Cobenfy (xanomeline and ...

The Company reported a net loss of approximately $8.4 million, or $0.25 per share, for the three months ended September 30, ...

A new study links hallucinogen-related emergency department visits to a 21-fold increased risk of schizophrenia compared to ...

The most common side effects of INVEGA HAFYERA® include: injection site reactions, weight gain, headache, upper respiratory ...

Researchers conducted a cohort study to assess the predictive value of plasma MMP9 in antipsychotic treatment response among patients with schizophrenia.

Even after controlling for a person’s existing substance use and mental health disorders, there remained a 3.5-fold increased ...

Individuals with emergency department visits involving hallucinogen use are at high risk of developing schizophrenia, ...

Its pipeline includes treatments for bipolar depression, agitation in Alzheimer’s disease, schizophrenia and Parkinson’s ...

Psychedelics have been growing in popularity across North America for recreational and therapeutic use, with celebrities like ...

New research highlights neuroglia (or glia cells) as critical players in mental health, potentially influencing conditions like depression and schizophrenia.

AbbVie (ABBV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Geoff Meacham ...

AbbVie’s ABBV mid-stage studies of emraclidine for schizophrenia failed to meet their primary endpoint. Shares of the company ...